AT-02 is under clinical development by Attralus and currently in Phase I for Primary Systemic Amyloidosis. According to GlobalData, Phase I drugs for Primary Systemic Amyloidosis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AT-02 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AT-02 overview
AT-02 is under development for the treatment of ATTR (transthyretin) and AL (light chain) amyloidosis and systemic amyloidosis other types. It comprises of amyloid-reactive peptide fused with an IgG1 antibody. It acts by targeting amyloid protein and developed based on Fc-fusion protein technology. It is administered through intravenous route.
Attralus overview
Attralus, formerly Aurora Bio, is a biotechnology company that develops and commercializes pan-amyloid removal (PAR) technologies and peptides for systemic amyloidosis. The company’s pipeline program includes AT-01, AT-02, AT-03, AT-04, AT-05, AT-06, AT-07 and others. Its AT-01, amyloid-specific imaging radiotracer detects amyloid light-chain (AL); and transthyretin (ATTR) amyloidosis in the heart, kidney, liver and spleen. The company operates its offices in California. Attralus is headquartered in South San Francisco, California, the US.
For a complete picture of AT-02’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
